December 5, 2023
Durin Technologies Receives Additional Funding to Accelerate Growth
​
Durin Technologies, Inc. today announced funding of $3.5 million led by Breakthrough Diagnostics, LLC. The funding will accelerate Durin’s next key stages of anticipated growth, involving commercialization of its novel diagnostic tests focusing on Alzheimer’s and Parkinson’s diseases and development of its next generation of diagnostic tests that detect other diseases and disorders at their earliest stages.
November 22, 2023
Durin Technologies, Inc., Appoints CEO
​
Durin Technologies, Inc., an innovator in neurodegenerative disease diagnostic test development and commercialization, today announced the appointment of Dr. Mert Sahin as Chief Executive Officer.
March 15, 2023
Researchers from Rowan and Durin Technologies announce highly accurate blood test for Alzheimer’s Disease
​
A team of researchers from Rowan-Virtua School of Osteopathic Medicine (Rowan-Virtua SOM) and Durin Technologies, Inc., have announced the results of a newly-designed blood test that can detect the presence of Alzheimer’s disease-related pathology up to 10 years before symptoms arise with a nearly 97 percent accuracy rate.
March 14, 2023
Autoantibody-Based Alzheimer's Test by Durin Technologies Moving Toward Potential Commercialization
​
Diagnostics firm Durin Technologies is moving toward commercialization of its blood-based test for the early detection of Alzheimer's disease.
December 23, 2019
​
South Jersey health care startup raises $3.5 million
​
A South Jersey life sciences company working on a test that can detect Alzheimer's at an early-stage has received a $3.5 million investment.